Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Our large observational study adds long-term survival to the mounting data supporting the use and safety of conservative surgery for low-risk, early-stage cervical carcinoma,” the researchers wrote.